Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP26082.RAy3ei05nirCD3bQ5Zkhgha_B3iX9xWdEtmm010gbdqAo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP26082.RAy3ei05nirCD3bQ5Zkhgha_B3iX9xWdEtmm010gbdqAo130_assertion type Assertion NP26082.RAy3ei05nirCD3bQ5Zkhgha_B3iX9xWdEtmm010gbdqAo130_head.
- NP26082.RAy3ei05nirCD3bQ5Zkhgha_B3iX9xWdEtmm010gbdqAo130_assertion description "[Based on previous studies comparing different recombinant tissue plasminogen activator (rt-PA) doses, we performed a clinical trial with 0.6 mg/kg, which is lower than the internationally approved dosage of 0.9 mg/kg, aiming to assess the efficacy and safety of alteplase in acute ischemic stroke for the Japanese.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP26082.RAy3ei05nirCD3bQ5Zkhgha_B3iX9xWdEtmm010gbdqAo130_provenance.
- NP26082.RAy3ei05nirCD3bQ5Zkhgha_B3iX9xWdEtmm010gbdqAo130_assertion evidence source_evidence_curated NP26082.RAy3ei05nirCD3bQ5Zkhgha_B3iX9xWdEtmm010gbdqAo130_provenance.
- NP26082.RAy3ei05nirCD3bQ5Zkhgha_B3iX9xWdEtmm010gbdqAo130_assertion SIO_000772 16763187 NP26082.RAy3ei05nirCD3bQ5Zkhgha_B3iX9xWdEtmm010gbdqAo130_provenance.
- NP26082.RAy3ei05nirCD3bQ5Zkhgha_B3iX9xWdEtmm010gbdqAo130_assertion wasDerivedFrom ctd_human-20130708 NP26082.RAy3ei05nirCD3bQ5Zkhgha_B3iX9xWdEtmm010gbdqAo130_provenance.
- NP26082.RAy3ei05nirCD3bQ5Zkhgha_B3iX9xWdEtmm010gbdqAo130_assertion wasGeneratedBy ECO_0000218 NP26082.RAy3ei05nirCD3bQ5Zkhgha_B3iX9xWdEtmm010gbdqAo130_provenance.